Technical Analysis for REGN - Regeneron Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 304.94 -1.01% -3.10
REGN closed down 1.01 percent on Friday, May 17, 2019, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical REGN trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup -1.01%
Lower Bollinger Band Walk Weakness -1.01%
Oversold Stochastic Weakness -1.01%
Calm After Storm Range Contraction -0.30%
Lower Bollinger Band Walk Weakness -0.30%
Multiple of Ten Bullish Other -0.30%
Lower Bollinger Band Touch Weakness -0.30%
Oversold Stochastic Weakness -0.30%

Older signals for REGN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage consist of EYLEA for the treatment of ophthalmologic diseases; and ZALTRAP for oncology. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN88 for rheumatoid arthritis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis and allergic asthma; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN1500, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Medicine Biotechnology Health Biopharmaceutical Pain Immunology Infectious Diseases Antibodies Monoclonal Antibodies Inflammation Disorders Rheumatoid Arthritis Cardiovascular Diseases Atopic Dermatitis Macular Edema Sanofi Breakthrough Therapy Allergic Asthma Immune Diseases Metastatic Colorectal Cancer Regeneron
Is REGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 442.0
52 Week Low 291.1
Average Volume 842,858
200-Day Moving Average 382.4077
50-Day Moving Average 370.419
20-Day Moving Average 328.753
10-Day Moving Average 316.24
Average True Range 10.699
ADX 41.46
+DI 12.3882
-DI 33.6114
Chandelier Exit (Long, 3 ATRs ) 335.923
Chandelier Exit (Short, 3 ATRs ) 329.4218
Upper Bollinger Band 360.2271
Lower Bollinger Band 297.2789
Percent B (%b) 0.12
BandWidth 19.147567
MACD Line -18.9702
MACD Signal Line -18.2868
MACD Histogram -0.6833
Fundamentals Value
Market Cap 32.33 Billion
Num Shares 106 Million
EPS 9.97
Price-to-Earnings (P/E) Ratio 30.59
Price-to-Sales 8.43
Price-to-Book 7.99
PEG Ratio 1.55
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 313.21
Resistance 3 (R3) 313.71 311.46 311.83
Resistance 2 (R2) 311.46 309.36 311.21 311.37
Resistance 1 (R1) 308.20 308.05 307.08 307.70 310.91
Pivot Point 305.95 305.95 305.39 305.70 305.95
Support 1 (S1) 302.69 303.85 301.57 302.19 298.97
Support 2 (S2) 300.44 302.54 300.19 298.51
Support 3 (S3) 297.18 300.44 298.05
Support 4 (S4) 296.68